生血宝合剂联合重组人促红细胞生长素治疗化疗相关性贫血的临床研究

Clinical Study on Shengxuebao Mixture Combined with Recombinant Human Erythropoietin in the Treatment of Chemotherapy-related Anemia

目的:观察生血宝合剂联合重组人促红细胞生长素(r Hu EPO)治疗化疗相关性贫血的临床疗效。方法:将纳入研究的155例患者随机分为治疗组和对照组,治疗组(78例)口服生血宝合剂配合r Hu EPO皮下注射,对照组(77例)仅皮下注射r Hu EPO,观察患者治疗前后血红蛋白(Hb)均值的变化和贫血治疗的临床有效率,以数字评分量表(NRS评分)评估患者的生活质量。结果:治疗第2、4、6、8周后,治疗组的Hb值水平与对照组相比较,差异有统计学意义,P<0.05;除对照组治疗2周,两组的Hb值均较治疗前升高,差异有统计学意义,P<0.05;治疗组的贫血治疗有效率为82.1%,对照组的为64.9%,差异有统计学意义,P<0.05;治疗后,治疗组和对照组的NRS评分分别为(30±5)分和(60±7)分,差异有统计学意义,P<0.05。结论:生血宝合剂联合r Hu EPO治疗化疗相关贫血疗效确切,能明显改善患者的生活质量。

Objective： To observe clinical effect of Shengxuebao mixture combined with recombinant human Erythropoietin（r Hu EPO） in the treatment of chemotherapy-related anemia. Methods： 155 cases admitted in our hospital were randomly divided into the treatment group and the control group. The treatment group with 78 cases were administered with Shengxuebao Mixture orally（15 ml each time, 3 times per day） and with r Hu EPO hypodermically（150 U/kg, 3 times per week）; while the control group with 77 casess were only administered with r Hu EPO hypodermically. Observed the changes of hemoglobin（Hb） and the clinical efficacy of anemia treatment before and after treatment, and evaluated the quality of life of patients with digital score scale（NRS）. Results： At the end of the second,fourth, sixth and eighth week of the treatment, the difference of the Hb level between the treatment group and the control group was statistically significant, P 0.05; and the two group＇s Hb was significantly higher than that before the treatment, the difference was statistically significant, P〈0.05; the treatment group＇s effective rate for the treatment of anemia was 82.1%, while the control group was64.9%, the difference was statistically significant, P〈0.05; after treatment, the treatment group and the control group NRS scores were（30±5） and（60±7）, the difference was statistically significant, P〈0.05. Conclusion： Shengxuebao mixture combined with recombinant human Erythropoietin（r Hu EPO） has evident effect on chemotherapy-related anemia, and can improve patients＇ life quality significantly.